Cosentyx Pen(Secukinumab)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$172.5M
Medicare cost, 2022
$172.5M
Medicare cost, 2022
Medicare drug plans spent on Cosentyx Pen (secukinumab) in 2024, for prescriptions and refills.
Medicare cost, 2022
$172.5M
Prescriptions
19K
$8,885.52 per claim
Patients
3,579
2,659 prescribers
Total spending
-
All plans
Questions and answers
How much does Medicare spend on Cosentyx Pen?
Medicare prescription drug plans paid $172.5M for Cosentyx Pen in 2022, for 19,411 prescriptions and refills to 3,579 patients. The average cost per claim was $8,885.52.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 2,659 | 19,411 | 3,579 | $172.5M |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through June 2026, 160,421 side-effect reports named secukinumab, the active ingredient of Cosentyx Pen (reports from 2012 on). 64,328 of them (40.1%) were serious, 8,611 named a death and 21,920 named a hospital stay. The reactions named most often were drug ineffective, psoriasis and pain. 57,680 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
160,421
9,198 in 2025 (-16.8% from 2024)
Serious
40.1%
64,328 reports
Deaths named
8,611
5.4% of reports
Hospital stays
21,920
13.7% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Cosentyx Pen?
160,421 reports from 2012 through June 2026 named secukinumab, the active ingredient of Cosentyx Pen. 64,328 of them (40.1%) were serious, 8,611 named a death and 21,920 named a hospital stay.
What are the most reported side effects of Cosentyx Pen?
29,187 reports named drug ineffective, the reaction named most often, followed by psoriasis (22,826) and pain (16,628). In the last 5 years the reaction named most often was drug ineffective (11,046 reports). A report can name several reactions.
How many side-effect reports named Cosentyx Pen in 2025?
9,198 reports were received in 2025 (-16.8% from 2024). 2026 so far: 3,008 reports through June 2026, and more keep arriving late.
Do side-effect reports prove that Cosentyx Pen caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Cosentyx Pen caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with secukinumab: Cosentyx Sensoready (2 Pens), Cosentyx Unoready Pen, Cosentyx Sensoready Pen, Cosentyx (2 Syringes), Cosentyx Syringe, Cosentyx, Cosentyx Pen (2 Pens)
- Makers on the stock market:
NVS·NVS drug pipeline - Drug approvals (2 approvals on file for secukinumab) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (secukinumab) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.